Cargando…

Overcoming multiple drug resistance mechanisms in medulloblastoma

INTRODUCTION: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Othman, Ramadhan T, Kimishi, Ioanna, Bradshaw, Tracey D, Storer, Lisa CD, Korshunov, Andrey, Pfister, Stefan M, Grundy, Richard G, Kerr, Ian D, Coyle, Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229867/
https://www.ncbi.nlm.nih.gov/pubmed/24887326
http://dx.doi.org/10.1186/2051-5960-2-57
_version_ 1782344182473424896
author Othman, Ramadhan T
Kimishi, Ioanna
Bradshaw, Tracey D
Storer, Lisa CD
Korshunov, Andrey
Pfister, Stefan M
Grundy, Richard G
Kerr, Ian D
Coyle, Beth
author_facet Othman, Ramadhan T
Kimishi, Ioanna
Bradshaw, Tracey D
Storer, Lisa CD
Korshunov, Andrey
Pfister, Stefan M
Grundy, Richard G
Kerr, Ian D
Coyle, Beth
author_sort Othman, Ramadhan T
collection PubMed
description INTRODUCTION: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines. RESULTS: We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase (MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain reaction, Western blotting and flow cytometry) in MB cell lines. Based on these findings, each pathway was then inhibited or circumvented and cell survival assessed using clonogenic assays. Inhibition of ABCB1 using vardenafil or verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines. Sensitivity to temozolomide (TMZ) was MGMT-dependent, but two novel imidazotetrazine derivatives (N-3 sulfoxide and N-3 propargyl TMZ analogues) demonstrated ≥7 fold and ≥3 fold more potent cytotoxicity respectively compared to TMZ in MGMT-expressing MB cell lines. Activity of the BAD mimetic ABT-737 was BCL2A1 and ABCB1 dependent, whereas the pan-BCL2 inhibitor obatoclax was effective as a single cytotoxic agent irrespective of MCL1, BCL2, BCL2A1, or ABCB1 expression. CONCLUSIONS: ABCB1 is associated with high-risk MB; hence, inhibition of ABCB1 by vardenafil may represent a valid approach in these patients. Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2051-5960-2-57) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4229867
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42298672014-11-14 Overcoming multiple drug resistance mechanisms in medulloblastoma Othman, Ramadhan T Kimishi, Ioanna Bradshaw, Tracey D Storer, Lisa CD Korshunov, Andrey Pfister, Stefan M Grundy, Richard G Kerr, Ian D Coyle, Beth Acta Neuropathol Commun Research INTRODUCTION: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines. RESULTS: We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase (MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain reaction, Western blotting and flow cytometry) in MB cell lines. Based on these findings, each pathway was then inhibited or circumvented and cell survival assessed using clonogenic assays. Inhibition of ABCB1 using vardenafil or verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines. Sensitivity to temozolomide (TMZ) was MGMT-dependent, but two novel imidazotetrazine derivatives (N-3 sulfoxide and N-3 propargyl TMZ analogues) demonstrated ≥7 fold and ≥3 fold more potent cytotoxicity respectively compared to TMZ in MGMT-expressing MB cell lines. Activity of the BAD mimetic ABT-737 was BCL2A1 and ABCB1 dependent, whereas the pan-BCL2 inhibitor obatoclax was effective as a single cytotoxic agent irrespective of MCL1, BCL2, BCL2A1, or ABCB1 expression. CONCLUSIONS: ABCB1 is associated with high-risk MB; hence, inhibition of ABCB1 by vardenafil may represent a valid approach in these patients. Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2051-5960-2-57) contains supplementary material, which is available to authorized users. BioMed Central 2014-05-30 /pmc/articles/PMC4229867/ /pubmed/24887326 http://dx.doi.org/10.1186/2051-5960-2-57 Text en © Othman et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Othman, Ramadhan T
Kimishi, Ioanna
Bradshaw, Tracey D
Storer, Lisa CD
Korshunov, Andrey
Pfister, Stefan M
Grundy, Richard G
Kerr, Ian D
Coyle, Beth
Overcoming multiple drug resistance mechanisms in medulloblastoma
title Overcoming multiple drug resistance mechanisms in medulloblastoma
title_full Overcoming multiple drug resistance mechanisms in medulloblastoma
title_fullStr Overcoming multiple drug resistance mechanisms in medulloblastoma
title_full_unstemmed Overcoming multiple drug resistance mechanisms in medulloblastoma
title_short Overcoming multiple drug resistance mechanisms in medulloblastoma
title_sort overcoming multiple drug resistance mechanisms in medulloblastoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229867/
https://www.ncbi.nlm.nih.gov/pubmed/24887326
http://dx.doi.org/10.1186/2051-5960-2-57
work_keys_str_mv AT othmanramadhant overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT kimishiioanna overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT bradshawtraceyd overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT storerlisacd overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT korshunovandrey overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT pfisterstefanm overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT grundyrichardg overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT kerriand overcomingmultipledrugresistancemechanismsinmedulloblastoma
AT coylebeth overcomingmultipledrugresistancemechanismsinmedulloblastoma